LEUMYE™
Comprehensive genomic profiling for myeloid neoplasms
Leumye™ analyses mutations and selected translocations in 90 key genes in myeloid neoplasm by targeted DNA sequencing (Leumye™ D), or in combination with whole transcriptome mRNA sequencing (Leumye™ DR) to detect a broader range of gene translocations and expression changes.
WHO IS IT FOR
All patients with myeloid neoplasms
- Acute myeloid leukemia (AML) and related neoplasms
- Myelodysplastic syndromes (MDS)
- Myeloproliferative neoplasms (MPN)
- MDS/MPN
SAMPLE TYPES
Peripheral blood or bone marrow
LET’S ACCELERATE PRECISION CANCER CARE, TOGETHER.
Learn more about our products and services or contact us today to discuss how we can partner together.
